Yazar "Baba, Burcu" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    CRUCIAL MARKERS SHOWING THE RISK OF CORONARY ARTERY DISEASE IN OBESITY: ADMA AND NEOPTERIN
    (Soc Medical Biochemists Serbia, 2020) Avci, Emre; Karabulut, Alpaslan; Avci, Avci Alp; Baba, Burcu; Bilgi, Cumhur
    Background: Obesity is responsible for high morbidity and mortality, both in developed and developing countries. It is associated with many chronic and metabolic diseases. Asymmetric dimethylarginine (ADMA) has been demonstrated to be a biomarker of endothelial dysfunction in humans and increased ADMA associated with cardiovascular disease (CVD) risk has been reported in many states. Neopterin (NP) produced by monocytes/macrophages in response to stimulation by interferon-gamma (IFN-gamma) is emphasized in recent findings. The current study aims to investigate ADMA and NP levels which may assume a role in guiding the early diagnosis of coronary artery disease in obesity. Methods: This is an original research study in which ADMA and NP levels of 50 patients (25 male/25 female) diagnosed with obesity were compared with those of 30 healthy individuals (15 male/15 female) as control. The high-performance liquid chromatography (HPLC) method was used while determining parameters. Results: ADMA and NP levels in obese individuals were found to be significantly higher than in those enrolled in the control. ADMA values were found to be higher in obese subjects (0.71 +/- 0.24 mu mol/L) as compared with levels found in healthy subjects (0.58 +/- 0.16 mu mol/L) (p<0.05). A significant increase of serum neopterin levels was found in obese subjects (8.8 +/- 3.5 mu mol/L) as compared with controls (4.9 +/- 1.69 mu mol/L) (p<0.05). Also, there was a strong positive correlation between NP and ADMA values in obese individuals (r=0.954). Conclusions: Our study revealed that obese subjects have higher ADMA and neopterin levels. These results demonstrated that both ADMA and NP levels may be potential risk factors for coronary heart disease in obesity.
  • Küçük Resim
    Öğe
    Evaluation of Zerumbone as an EGFR Tyrosine Kinase Inhibitor by Molecular Docking Method
    (University of Ankara, 2023) Yonar, Dilek; Baba, Burcu; Karayel, Arzu
    Objective: EGFR-TK domain is of great importance in the initiation and progression of various cancer types, especially lung cancer. The existing EGFR-TK inhibitors have numerous side effects, which make them improper to be utilized as cancer therapeutics. In this study, we aimed to analyze the activity of zerumbone as an anticancer agent targeting EGFR by molecular docking approach and to evaluate its activity in comparison with curcumin. Material and Method: MEP and HOMO-LUMO analyses were achieved at B3LYP/6-31G(D,P) level to evaluate electrostatic interactions that affect binding of EGFR with zerumbone and curcumin. Their binding energies were determined by molecular docking and compared with erlotinib as reference ligand. Result and Discussion: Docking studies showed higher bindings (lower binding energy) for curcumin and zerumbone with binding energies -8.0 and -7.6 kcal/mol, respectively, compared to erlotinib (-7.3 kcal/mol). However, there is no significant difference between them. The ?E energy gap of zerumbone was 5.09 eV which implies that this compound has more stability in comparison with curcumin (?E=3.68 eV) and erlotinib (?E=4.29eV). Also, zerumbone showed strong hydrogen bond interactions with EGFR, making it candidate as EGFR inhibitor, as did both in curcumin and erlotinib. It was concluded that zerumbone may have potential for inhibitory activity against EGFRTK.